InvestorsHub Logo
Followers 18
Posts 1387
Boards Moderated 0
Alias Born 10/21/2015

Re: Money $hot post# 6998

Sunday, 03/29/2020 10:51:32 AM

Sunday, March 29, 2020 10:51:32 AM

Post# of 16682
Your timeline is reasonable. See point 3 below for the key step which must be considered for us to determine timelines for scientific trials.

For those who don't work in science-related industry, here are a few key steps required to get the ball rolling and get some scientific data aka the stuff that is going to send this stock to the moon... and I am not going to waste a lot of time repeating what's spelled out very clearly in the BioPub interview Algernon did because that was very clear and anyone investing here should have watched that.

1. Pre-clinical research: As stated in BioPub interview, having data in animal studies that shows your drug has therapeutic efficacy (aka it actually treats the disease of interest). We have this done. As Smoki pointed out... one aspect of our drug pipeline is for idiopathic pulmonary fibrosis and chronic cough... and our lead outperforms the best drug big pharma has... you better not kid yourself, big pharma is watching, they definitely saw the headlines... they always watch for competition...

Algernon Pharmaceuticals’ NP-120 (Ifenprodil) Outperforms Merck’s Phase 3 Drug MK-7264 (Gefapixant) in an Acute Cough Study by 110%

. Further, we know that Ifenprodil works for severe acute lung injury and acute respiratory distress syndrome which is what is killing people who get COVID-19, novel coronavirus. These preclinical testing steps save us a lot of time and show that the drug works.

2. Safety and early phase trials: these usually cost hundreds of millions. We are using repurposed drugs. We have patents protecting Ifenprodil for respiratory diseases. We are saving hundreds of millions. We are doing some FDA-registered clinical trial testing in the USA (FDA registered Algernon trial. We will show it's safe for injection by IV. We will show it works for acute lung injury and cough.

3. Clinical trials: Everybody investing here wants to score big and see the share price in the several dollars range. That's obvious. So how do we get that? Solid scientific data that shows our drug outperforms others (e.g. chronic cough and idiopathic pulmonary fibrosis). Or, our drug saves lives from the lung injury causes by COVID. We have NOVOTECH which is a certified CRO which is going to be running our trials. We have funding. We have NOVOTECH investing there own money (skin in the game) in Algernon. FDA and medical regulatory authorities in Australia and South Korea will fast track ifenprofil for COVID-19 related use. 2-4 weeks is reasonable to know how the drug is working, I agree. However, the number one key limiting factor to determine when the trial starts, is when Mark Williams finishes the ethics approval and study protocol. That's the time consuming step.. However, I am of the belief he's working his butt off. Look at all the news releases. Look at the recent FDA trial registration. I think these fellas know there is money to be made and they aren't playing around. Get ready for blast off.